UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2018 Earnings Conference Call Transcript

Feb 28, 2019 • 08:30 am ET


UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2018 Earnings Conference Call Transcript


Loading Event

Loading Transcript


Good morning, ladies and gentlemen. Thank you for standing by, and welcome to UroGen Pharma's Fourth Quarter and Full Year 2018 Financial Results and Business Update Conference Call.

It is now my pleasure to turn the call over to Kate Bechtold, Director of Corporate Communications and Investor Relations for UroGen Pharma. Please go ahead.

Kate Bechtold

Thank you, operator. Good morning, everyone, and welcome to UroGen Pharma's fourth quarter and full-year 2018 financial results and business update conference call.

Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter and full-year ended December 31, 2018. The press release can be accessed on the Investors portion of our website at investors.urogen.com.

Joining me on the call today are Liz Barrett, President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; and Peter Pfreundschuh, Chief Financial Officer. Liz will provide a summary of our recent corporate developments; and Mark will share clinical development and regulatory updates. Peter will then provide an overview of our financial highlights for the fourth quarter and full year 2018, before we open up the call for questions. Joining us for the Q&A portion of this call will be Stephen Mullennix, Chief Operating Officer.

As a reminder, during today's call, we will be making certain forward-looking statements. Various remarks that we make during this call about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of UroGen Pharma's annual report on Form 10-K to be filed with the SEC today, and other filings that UroGen Pharma makes with the SEC from time to time. We encourage all investors to read the company's annual report on Form 10-K and the company's other SEC filings. These documents are available under the SEC filings section of the Investors page of UroGen's website at investors.urogen.com.

In addition, all information we provide on this conference call represents our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise.

I will now turn the call over to Liz.

Liz Barrett

Thank you, Kate. Good morning, everyone, and thank you for joining our conference call.

As many of you may know, I joined the UroGen team in the beginning of January. So, this is my first call as CEO of the company. I am absolutely delighted to have joined UroGen at such a defining time in the Company's evolution. Since, I have not had a chance to personally introduce myself to everyone dialed into